Skip to main content

PHROG: A randomized, placebo-controlled, double-blinded cross-over study of the pharmacologic action of a GPR119 agonist on glucagon counter-regulation during insulin-induced hypoglycemia in Type 1 diabetes mellitus.

PHROG: A randomized, placebo-controlled, double-blinded cross-over study of the pharmacologic action of a GPR119 agonist on glucagon counter-regulation during insulin-induced hypoglycemia in Type 1 diabetes mellitus.

Associated Conditions

Type 1

Principal Investigator

Sponsor

AdventHealth

People with type 1 diabetes are at high risk of developing hypoglycemia because of insulin treatment and because their body is less effective at increasing the levels of sugar in their blood when it is low. In this research study we will test if a specific research medication could increase the response to low blood glucose in people with type 1 diabetes. The response of the body to low blood sugar will be measured in healthy people as a reference point.

This study is currently enrolling.


Interested in Participating?

Please call (407) 303-7193 or fill out the Contact Form below for more information.